PRRT2 / Proline-rich transmembrane protein 2 · IHC design guide

Design Immunohistochemistry for PRRT2

Plan PRRT2 chromogenic IHC in paraffin sections using cerebellar granular-layer cells and cortical neuropil as positive controls (HPA tissue IHC). Keep fixation consistent and score the observed cytoplasmic CNS signal (HPA tissue IHC), while treating synaptic-membrane localization as a molecular expectation (UniProt).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for PRRT2 (IHC for PRRT2): expected localisation Cytoplasmic CNS staining (HPA tissue IHC); synaptic membranes are a molecular expectation (UniProt), antibody A02707, validated IHC image, and IHC protocol steps — Printable **PRRT2** IHC protocol sheet — expected localisation Cytoplasmic CNS staining (HPA tissue IHC); synaptic membranes are a molecular expectation (UniProt), antibody A02707, controls and protocol steps. Open the full PRRT2 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

PRRT2 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic CNS staining (HPA tissue IHC); synaptic membranes are a molecular expectation (UniProt)
	Staining pattern	Cytoplasmic signal in cerebellar granular-layer cells and cortical neuropil (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen)
	Positive control ⓘ	Cerebellum+1 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A02707)
	Caveat	Brain staining varies by cell type: caudate glia are not detected (HPA tissue IHC)
	Regulation	Expression regulation is not annotated (UniProt)
	Isoform / epitope	3 isoforms; cytoplasmic/extracellular epitope unknown (UniProt)

Section 1

Recommended PRRT2 IHC & IF Protocols

The catalog antibody’s IHC-P protocol is followed by three published PRRT2 immunoperoxidase protocols: paraffin and cryostat sections, human tissue microarrays, and mouse vibratome sections prepared for electron microscopy.

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Tissue sections; selected-image fixative not specified (standard IHC workflow)
Fixation	Image fixative and duration unreported (datasheet A02707); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-PRRT2, 1:100–1:500 starting range (standard)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	PRRT2-positive staining in cells in granular layer of cerebellum (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in CNS. No signal in the no-primary control.

💡Decision noteStart with citrate pH 6.0 heat retrieval at 95–98 °C for 20 min on paraffin sections (page retrieval rule); adjust against the published conditions for the chosen sample.

Section 2

What Is the Expected PRRT2 Staining Pattern?

PRRT2 is associated with synaptic and other neuronal membranes, with a transmembrane segment at residues 318–338 (UniProt Q7Z6L0 topology and subcellular location). In tissue IHC, expect cytoplasmic staining in the CNS, especially granular-layer cells in cerebellum and neuropil in cerebral cortex (HPA: High in both; tissue IHC reliability: Enhanced). Interpret the slide at the resolution of chromogenic IHC rather than requiring a sharp membrane outline.

What am I looking at on my slide?
Strong staining in cerebellar granular-layer cells and cerebral-cortex neuropil (HPA: High in both).	This matches the reported CNS pattern (HPA: cytoplasmic expression in CNS). The neuropil result fits PRRT2's synaptic and neuronal-process locations (UniProt Q7Z6L0 subcellular location); a crisp cell-border outline is not required in chromogenic sections (general IHC practice).
Predominantly nuclear staining, with little of the expected CNS pattern (HPA: High in cerebellar granular-layer cells and cortical neuropil).	Treat this as a localisation mismatch: UniProt places PRRT2 at neuronal membranes, synapses and vesicle membranes, without a nuclear location (UniProt Q7Z6L0 subcellular location). Review specificity and staining controls before scoring it as PRRT2 (general IHC practice).
Strong signal in a cell type reported as undetected, such as adipocytes in adipose tissue (HPA: Not detected).	This conflicts with the cited tissue observation (HPA: adipose-tissue adipocytes, Not detected). Cross-reactivity or endogenous detection activity is possible, not proven; compare a control section and the expected CNS pattern before assigning target expression (general IHC practice).
Diffuse colour across cells and tissue spaces, without a recognisable granular-layer or neuropil pattern (HPA: High in those sites).	Uniform background limits interpretation of the compartment and cell type (general IHC practice). Inspect the negative detection control and blocking and wash conditions; diffuse colour alone does not reproduce the reported PRRT2 tissue distribution (HPA: cytoplasmic CNS profile).
No convincing staining in cerebellar granular-layer cells or cerebral-cortex neuropil (HPA: High in both).	A known-positive comparison has failed relative to the HPA tissue pattern. Check section integrity, retrieval, antibody incubation and detection with appropriate controls (general IHC practice); this result alone cannot establish absence of PRRT2 in the specimen.

💡Expected PRRT2 appearanceCall the IHC result positive when granular-layer cells in cerebellum or neuropil in cerebral cortex show strong, interpretable CNS staining (HPA: High; cytoplasmic CNS profile), consistent with neuronal membrane and synaptic localisation (UniProt Q7Z6L0); isolated strong staining in an HPA-undetected cell type is a specificity concern (HPA: adipose-tissue adipocytes, Not detected).

How each factor affects the staining
Tissue and cell selection (HPA: tissue IHC).	Cerebellar granular-layer cells and cerebral-cortex neuropil provide reported high-signal references (HPA: High in both). Adipose-tissue adipocytes and adrenal glandular cells are reported as undetected (HPA: Not detected); use these comparisons by cell type, not as proof that every cell in those tissues lacks PRRT2.
Compartment and section resolution (UniProt Q7Z6L0 topology; HPA: tissue IHC).	PRRT2 has a transmembrane segment at 318–338 and annotated neuronal membrane and vesicle locations (UniProt Q7Z6L0). HPA describes cytoplasmic CNS staining in tissue IHC (HPA: profile). At chromogenic resolution, assess the reported tissue pattern without demanding a continuous plasma-membrane rim (general IHC practice).
IHC antibody validation (HPA: antibody records).	HPA014447 and HPA048045 are listed as IHC Enhanced (HPA: antibody records), while the tissue profile has Enhanced reliability from staining and RNA consistency (HPA: reliability description). These labels support comparison with the reported pattern; they do not establish specificity for every preparation or staining condition (general IHC practice).
Isoforms and epitope coverage (UniProt Q7Z6L0).	UniProt lists 3 isoforms (UniProt Q7Z6L0 isoforms). The supplied evidence gives no antibody epitope or isoform coverage, so an unexpected result cannot be attributed to a particular isoform from these records alone; confirm the IHC-validated antibody's documented target region before making an isoform claim.
IF/ICC comparison (HPA: subcellular ICC-IF).	Q: Should IF/ICC look identical to tissue IHC? A: HPA reports supported plasma-membrane localisation by ICC-IF, with images from AF22, SH-SY5Y and U2OS (HPA: subcellular ICC-IF). Tissue IHC instead reports cytoplasmic CNS staining (HPA: tissue IHC); compare each preparation with its own evidence.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Positive-control CNS section is blank despite reported high staining (HPA: cerebellar granular-layer cells; cortical neuropil).	An assay step may have failed; absence of colour alone does not identify which step (general IHC practice).	Check section integrity and reagent controls, then review retrieval, primary-antibody incubation and chromogenic detection in sequence (general IHC practice). Do not call the test specimen negative until the positive control works.
Staining is mainly nuclear, unlike annotated neuronal membrane locations (UniProt Q7Z6L0).	The localisation conflicts with the UniProt annotation; nonspecific staining or interpretation error is possible (general IHC practice).	Recheck the counterstain and cellular boundaries, compare the positive CNS control, and assess an appropriate primary-antibody control (general IHC practice). Record the nuclear signal as unresolved until specificity is supported.
Strong colour appears in adipose-tissue adipocytes reported as undetected (HPA: Not detected).	Cross-reactivity or endogenous detection activity could contribute; the HPA comparison alone cannot distinguish them (general IHC practice).	Compare a primary-omission control and the expected CNS-positive section, and review endogenous-activity blocking appropriate to the detection chemistry (general IHC practice).
The whole section has diffuse colour that obscures the reported CNS pattern (HPA: cytoplasmic CNS profile).	Nonspecific antibody binding, incomplete blocking or inadequate washing may elevate background (general IHC practice).	Inspect the control section, then optimise blocking, wash conditions and the IHC-validated antibody's documented working dilution (general IHC practice); no target-specific dilution is supplied here.
Neuropil stains, but individual neuronal membrane outlines are indistinct (HPA: cerebral-cortex neuropil, High).	Chromogenic tissue IHC may not resolve fine synaptic membranes individually (general IHC practice), although UniProt annotates synaptic membrane locations (UniProt Q7Z6L0).	Score the reported neuropil distribution and its controls (HPA: cerebral-cortex neuropil, High); avoid treating lack of a crisp membrane rim alone as a failed result (general IHC practice).
A low-signal tissue appears positive, such as lung macrophages or kidney tubular cells (HPA: Low in both).	Low reported staining can be genuine, while background can be harder to distinguish at low intensity (HPA: Low; general IHC practice).	Interpret the named cell type and compartment against control sections, and compare with high-signal CNS tissue (HPA: cerebellar granular-layer cells and cortical neuropil, High); avoid scoring the entire organ as uniformly positive.

Source: UniProt Q7Z6L0 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing PRRT2 staining

A02707 · IHCImmunohistochemistry of PRRT2 in rat brain tissue with PRRT2 antibody at 2.5 μg/ml.

A02707 · IFImmunofluorescence of PRRT2 in rat brain tissue with PRRT2 antibody at 20 μg/ml.

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000167371-PRRT2/tissue/cerebral+cortex#imid_4121904

HPA · CerebellumHuman Protein Atlas IHC, Cerebellum. Source: https://www.proteinatlas.org/ENSG00000167371-PRRT2/tissue/cerebellum#imid_4121915

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000167371-PRRT2/tissue/colon#imid_4121846

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000167371-PRRT2/tissue/liver#imid_4121847

HPA · ICC-IF AF22Human Protein Atlas immunofluorescence, AF22, antibody HPA019203; green = PRRT2, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for PRRT2 IHC & IF

🧪Run cerebellum first: cells in the granular layer should stain (HPA: High in cerebellar granular-layer cells). Use adipose tissue as the negative tissue, where adipocytes are not detected (HPA: Not detected in adipocytes); on the cerebellar slide, assess morphologically unstained cells as internal background without assuming every cell outside the granular layer is PRRT2-negative.

Positive control tissue: Cerebellum (Cells in granular layer, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PRRT2 in AF22, SH-SY5Y, U2OS, with annotated localisation: Plasma membrane (supported) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control and a host-species-matched isotype control for a monoclonal primary or matched nonimmune IgG for a polyclonal primary; use PRRT2 knockout tissue as a biological specificity control if available. Block endogenous peroxidase for chromogenic IHC, assess endogenous biotin if using avidin–biotin detection, and check brain autofluorescence for IF.

⚠️Feasibility: A PRRT2-specific fixation window, fixation effect, and antigen-retrieval dependency are unreported in the supplied evidence; optimize retrieval empirically for paraffin sections. The selected A02707 rat brain IHC caption reports 2.5 μg/mL but leaves the fixative unreported (selected A02707 tissue-IHC caption). The evidence does not establish whether frozen sections or IF are easier; brain autofluorescence may complicate IF interpretation.

HPA tissue IHC evidence for PRRT2

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Cerebellum	Cells in granular layer	High	Protein (IHC)	HPA →
Cerebral cortex	Neuropil	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Appendix	Glandular cells	Not detected	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →

Section 3

Advanced PRRT2 IHC Tips

Use compartment-aware controls and matched tissue processing to troubleshoot PRRT2 staining in chromogenic paraffin-section IHC (UniProt Q7Z6L0 localisation; standard IHC practice).

How should I retrieve PRRT2 when paraffin-section staining is weak?

Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 min (this page’s antigen-retrieval protocol). Let sections cool in buffer, then compare staining with an otherwise matched section processed without retrieval (standard IHC practice). If staining remains weak, compare a second retrieval condition on adjacent sections while holding antibody concentration and detection constant; treat it as an optimisation, not an established PRRT2 condition (standard IHC practice). Assess signal in cerebellar granular-layer cells or cerebral-cortex neuropil before judging retrieval success (HPA: High in both). Reject conditions that raise diffuse background or damage tissue architecture (standard IHC practice).

Could fixation explain variable PRRT2 staining between paraffin blocks?

Target-specific fixation sensitivity is unknown because the supplied PRRT2 tissue-IHC caption does not state a fixative (A02707 tissue-IHC caption). Record each block’s fixation and processing history, then compare sections stained in the same run with the same retrieval and detection settings (standard IHC practice). If a block stains poorly, include a well-preserved positive tissue section and examine morphology before changing antibody concentration (HPA: High in cerebellar granular-layer cells and cortical neuropil; standard IHC practice). Avoid assigning weak staining to PRRT2’s membrane topology or modified residues without a direct fixation comparison (UniProt Q7Z6L0 topology and modified residues; standard IHC practice).

Where should convincing PRRT2 chromogenic staining appear?

Look for staining associated with neuronal processes and synaptic regions, allowing cytoplasmic profiles in CNS tissue (UniProt Q7Z6L0 subcellular localisation; HPA: cytoplasmic expression in CNS). Cerebellar granular-layer cells and cerebral-cortex neuropil are useful positive reference areas because both have High tissue-IHC signal (HPA: cerebellum and cerebral cortex). PRRT2 is annotated at presynaptic membranes, synaptic vesicle membranes, postsynaptic density membranes, axons and dendritic spines (UniProt Q7Z6L0 subcellular localisation). Compare these patterns with tissue architecture and a matched negative control rather than calling any diffuse brown deposit positive (standard IHC practice). HPA ICC/IF also supports plasma-membrane localisation (HPA subcellular: supported).

How can epitope placement change the PRRT2 IHC pattern?

PRRT2 has 3 annotated isoforms, so check which sequence the antibody immunogen covers before comparing specimens or antibodies (UniProt Q7Z6L0 isoforms; standard IHC practice). The annotated transmembrane segment spans residues 318–338, while residues 1–268 and 290–317 are cytoplasmic (UniProt Q7Z6L0 topology). An epitope in a variable sequence could alter isoform coverage; do not assume shared recognition without epitope information (UniProt Q7Z6L0 isoforms; standard IHC practice). Phosphorylation is annotated at residues including 28, 74, 238 and 248 (UniProt Q7Z6L0 modified residues). Consider modification-dependent recognition only if the antibody’s epitope and validation support it (standard IHC practice).

How can I check PRRT2 localisation by IF alongside chromogenic IHC?

Multiplex PRRT2 with a neuronal marker suited to the expected granular-layer cells, and inspect cortical neuropil separately from cell bodies (HPA: High in cerebellar granular-layer cells and cerebral-cortex neuropil; standard IF practice). Choose a fluorophore channel after measuring tissue autofluorescence, favouring a spectrally separated, longer-wavelength signal where background is lower (standard IF practice). If the antibody epitope is cytoplasmic, include controlled permeabilisation; if extracellular, compare staining before permeabilisation, because accessibility depends on membrane orientation (UniProt Q7Z6L0 topology; standard IF practice). Use single-label and no-primary controls to assess bleed-through and background (standard IF practice). Interpret agreement with chromogenic IHC by compartment, since the readouts resolve tissue detail differently (standard IHC/IF practice).

What should I change when PRRT2 DAB staining is widespread?

Check a no-primary control for nonspecific detection and a peroxidase-block control for endogenous enzyme activity before interpreting brown signal (standard chromogenic IHC practice). Compare background with the expected CNS-enriched pattern: granular-layer cells and cortical neuropil have High signal, while adipocytes in adipose tissue are Not detected (HPA: tissue IHC). Reduce primary-antibody concentration from the tested image condition of 2.5 µg/ml only through a matched titration; the caption reports that concentration for rat brain tissue without stating fixation (A02707 tissue-IHC caption; standard IHC practice). Shorten DAB development or improve washing when controls show diffuse deposits, and retain identical settings across compared sections (standard IHC practice).

How should I score PRRT2 across paraffin tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define regions before scoring, separating cerebellar granular-layer cells from cortical neuropil because their staining occupies different structures (HPA: High in both; standard IHC practice). For granular-layer cells, report the percentage of positive cells or an H-score based on intensity and positive-cell fraction (standard IHC practice). For neuropil, measure thresholded stained area or optical density per mm² of intact region rather than forcing a cell-based score (standard IHC practice). Normalise to the analysed tissue area or eligible cell count, and use the same threshold, counterstain and DAB development across samples (standard IHC practice). Record excluded folds, edges and damaged regions (standard IHC practice).

How do I distinguish true PRRT2 staining from artefact?

A plausible positive follows CNS structures such as granular-layer cells or cortical neuropil and is compatible with PRRT2’s synaptic and membrane localisation (HPA: tissue IHC; UniProt Q7Z6L0 subcellular localisation). Strong staining confined to tissue edges, folds or necrotic areas warrants review of morphology and matched controls (standard IHC practice). Brown signal that persists without primary antibody or after an inadequate peroxidase block can reflect detection artefact or endogenous enzyme activity (standard chromogenic IHC practice). Be cautious with a dominant nuclear pattern, which does not match the supplied localisation annotations (UniProt Q7Z6L0 subcellular localisation; HPA subcellular: plasma membrane). Compare the same compartments in a positive reference and negative control before assigning biological meaning (standard IHC practice).

Boster reagents

Best PRRT2 / Proline-rich transmembrane protein 2 IHC Antibodies

A02707 has rat-brain IHC and IF images (catalog image captions); its listed applications include IHC-P and IF, with Human, Mouse, and Rat reactivity (catalog applications and reactivity).

Real IHC data Immunohistochemistry of PRRT2 in rat brain tissue with PRRT2 antibody at 2.5 μg/ml.

Anti-PRRT2 Antibody

Cat # A02707

View product →

A02707 will render with an IHC image of rat brain tissue at 2.5 μg/ml (IHC image caption). Its IF image shows rat brain tissue at 20 μg/ml (IF image caption); the catalog lists Human, Mouse, and Rat reactivity (catalog reactivity).

Which to pick: Choose A02707 for tissue IHC-P (catalog applications); its IHC image shows rat brain tissue, but the caption does not report the fixative (IHC image caption). Choose A02707 for tissue IF (catalog applications; IF image caption); ICC validation is not listed (catalog applications). For other species, A02707 lists Human, Mouse, and Rat reactivity, while the supplied IHC and IF images show rat tissue (catalog reactivity; IHC and IF image captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q7Z6L0 (PRRT2_HUMAN, Proline-rich transmembrane protein 2).
Human Protein Atlas. PRRT2 tissue IHC expression (reliability: Enhanced).
Human Protein Atlas. PRRT2 subcellular location (ICC-IF): Localized to the plasma membrane..
Human Protein Atlas. PRRT2 antibody validation summary (3 antibodies).
Presynaptic PRRT2 Deficiency Causes Cerebellar Dysfunction and Paroxysmal Kinesigenic Dyskinesia. Neuroscience 2020 — PMC9547552.
Aberrant transcriptional networks in step-wise neurogenesis of paroxysmal kinesigenic dyskinesia-induced pluripotent stem cells. Oncotarget 2016 — PMC5288209.
PRRT2 deficiency induces paroxysmal kinesigenic dyskinesia by regulating synaptic transmission in cerebellum. Cell research 2018 — PMC5752836.
Proline-Rich Transmembrane Protein 2 Is Variably Expressed Across Excitatory and Inhibitory Neurons in Mouse Motor Circuits. The Journal of comparative neurology 2026 — PMC13238401.
PubMed PMID:14702039 — UniProt-cited evidence.
PubMed PMID:16303743 — UniProt-cited evidence.
PubMed PMID:17974005 — UniProt-cited evidence.

Immunohistochemistry protocol sheet for PRRT2 (Proline-rich transmembrane protein 2). Expected localisation Cytoplasmic CNS staining (HPA tissue IHC); synaptic membranes are a molecular expectation (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A02707 at 1:100–1:500 (standard starting range) (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Cells in granular layer); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A02707); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-PRRT2, 1:100–1:500 starting range (standard); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A02707); Caveat: Brain staining varies by cell type: caudate glia are not detected (HPA tissue IHC); Isoform / epitope: 3 isoforms; cytoplasmic/extracellular epitope unknown (UniProt); Regulation: Expression regulation is not annotated (UniProt). Evidence: UniProt Q7Z6L0, HPA tissue IHC · Enhanced, HPA ICC-IF · plasma membrane., Datasheet A02707, PMC9547552, PMC5288209. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/PRRT2/immunohistochemistry-ihc-guide.